S-1/A1a2225205zs-1a.htmS-1/AUse these links to rapidly review the documentTABLE OF CONTENTSINDEX TO CONSOLIDATED FINANCIAL STATEMENTS GLAUKOS CORPORATIONTable of ContentsAs filed with the Securities and Exchange Commission on June 23, 2015.Registration No. 333-204091UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549Amendment No. 3toFORM S-1REGISTRATION STATEMENTUNDERTHE SECURITIES ACT OF 1933GLAUKOS CORPORATION(Exact name of registrant as specified in its charter)Delaware(State or other jurisdiction ofincorporation or organization)3841(Primary Standard IndustrialClassification Code Number)33-0945406(I.R.S. EmployerIdentification No.)26051 Merit Circle, Suite 103Laguna Hills, California 92653(949) 367-9600(Address, including zip code, and telephone number, includingarea code, of registrant's principal executive offices)Thomas W.
to take advantage of certain reduced public company reporting requirements for this prospectus and future filings.Per shareTotalInitial public offering price$$Underwriting discounts and commissions(1)$$Proceeds to Glaukos Corporation, before expenses$$(1)See
at this facility could materially affect our ability to operate and produce saleable products and could shut down our manufacturing capacity for an extended period;•Failure to secure and maintain adequate coverage or reimbursement by third-party payors in the United States for
a cost or in quantities sufficient to make these products commercially viable or to maintain current operating margins.We depend on a limited number of third-party suppliers for certain components, and the loss of any of these suppliers, or their inability to provide us with an adequate
including:•greater financial and human resources for product development, sales and marketing and patent litigation;•significantly greater name recognition;19Table of Contents•longer operating histories;•established relationships with healthcare professionals, customers and third-party payors;•additional lines of products, and the ability to offer rebates or bundle products to offer higher discounts or
growth, expected operating results and financial condition.The safety and efficacy of the iStent and our other products are not yet supported by long-term clinical data in large numbers of patients.
experience volatility due to a number of factors, many of which are beyond our control, including:•our ability to drive increased sales of our products;•our ability to establish and maintain an effective and dedicated sales organization;•fluctuations in the demand for our products;•pricing pressure applicable to our products, including adverse third-party coverage and reimbursement outcomes;•results of clinical research and trials on our products;•fluctuations in the number of cataract procedures performed by our customers, which could decrease significantly during
holiday seasons and summer months, when significant numbers of physicians and patients may schedule vacations;21Table of Contents•timing of new product offerings, acquisitions, licenses or other significant events by us or our competitors;•deferrals of customer orders in anticipation of the introduction of new products or product enhancements by us;•regulatory approvals and legislative changes affecting the products we may offer or those of our competitors;•interruption in the manufacturing or distribution of our products;•the ability of our suppliers to timely provide us with an adequate supply of product components;•the effect of competing technological, industry and market developments;•changes in our ability to obtain regulatory clearance or approval for our products or to obtain or maintain our CE
including our ability to:•properly identify and anticipate customer needs;•commercialize new products in a cost-effective and timely manner;•manufacture and deliver products in sufficient volumes on time;•obtain regulatory approval for new products;22Table of Contents•receive adequate coverage and reimbursement for procedures performed with our products;•differentiate our offerings from competitors' offerings;•achieve positive clinical outcomes;•satisfy the increased demands from healthcare payors, providers and patients for lower-cost procedures;•innovate and develop new materials, product designs and surgical techniques; and•provide adequate medical and consumer education relating to new products and attract key ophthalmologists and other eye
challenges, including:•new and increased responsibilities for our management team;•increased pressure on our operating and financial systems, controls and reporting systems;•the need to hire, train and manage additional qualified personnel;•management of an increasing number of relationships with our customers, suppliers and other third parties;•strain on our ability to source a larger supply of components that meet our required specifications on a timely basis;
condition and operating results could be adversely affected.Our iDose implant will be regulated as a drug and be subject to a different regulatory approval process than our other products in development.
this drug delivery implant into clinical testing or in obtaining FDA approval, and our long-term business prospects could be harmed.Our business requires substantial capital and operating expenditures to operate and grow.Although we generate net sales from sales of our first FDA-approved product, theiStent, and are conducting this offering, we may
regulatory approval for commercial sale;•scale-up our manufacturing operations;•pursue additional research and development;•defend, in litigation or otherwise, any claims that we infringe third-party patent or other intellectual property rights;
property rights;•the terms and timing of any collaborative, licensing and other arrangements that we may establish;•the cost and timing of regulatory approvals;•the cost and timing of establishing sales, marketing and distribution capabilities;•the cost of establishing clinical and commercial supplies of our products and any products that we may develop;•the effect of competing technological and market developments;•licensing technologies for future development; and•the extent to which we acquire or invest in businesses, products and technologies, although we currently have no
financial condition.Planned expansion into new markets outside of the United States will subject us to additional business and regulatory risks, and there can be no assurance that our products
ability of patients to elect to privately pay for theiStentand our other products;•difficulties in enforcing intellectual property rights;•pricing pressure;•required compliance with existing and changing foreign regulatory requirements and laws;•laws and business practices favoring local companies;•longer sales and payment cycles;•difficulties in enforcing agreements and collecting receivables through certain foreign legal systems;•political and economic instability;•foreign currency risks that could adversely affect our financial results;•potentially adverse tax consequences, tariffs and other trade barriers;•exposure to liabilities under anti-corruption and anti-money laundering laws, including the U.S. Foreign Corrupt
which would have a material adverse effect on our business.Legislative or regulatory reform of the healthcare system may affect our ability to sell our products profitably.In the United States and in certain foreign jurisdictions, there have been a number of legislative and regulatory proposals to change
medical devices is adopted, most likely in 2015 or 2016.The clinical trial process required to obtain regulatory approvals is lengthy and expensive with uncertain outcomes, and could result in delays in new product introductions.Because of the indication we chose to pursue for theiStent, the FDA required that we
you that we will receive the requisite or timely approvals for commercialization of this product candidate.Failure to comply with post-marketing regulatory requirements could subject us to enforcement actions, including substantial penalties, and might require us to recall or